Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. The full press release is available at https://ibn.fm/1QdP7.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s lead candidates target major depressive disorder (MDD) and generalized anxiety disorder (GAD), areas with significant unmet medical needs. HLP003, a proprietary NSA, is in Phase 3 clinical development for the adjunctive treatment of MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, also a proprietary NSA, is in Phase 2 for GAD. Additionally, Helus Pharma maintains an extensive research portfolio of investigational NSAs.
The company’s participation in the Jefferies conference underscores its commitment to advancing mental health treatments and engaging with the investment community. The fireside chat will likely cover clinical progress, regulatory milestones, and the broader potential of NSAs to provide durable improvements in mental health. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates, visit www.helus.com or follow the team on social media platforms. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.